With the interaction between the MUC1 C-terminal subunit (MUC1-C) and receptor tyrosine kinases at the cell membrane, the MUC1-C inhibitor has been studied as a potential therapeutic intervention for breast cancer [88]. This evidence concerns the gene MUC1 and breast carcinoma.